seldi‐tof proteinchip reader  (Ciphergen inc)

Journal: BMC Neurology

Article Title: Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS

doi: 10.1186/1471-2377-10-112

Figure Lengend Snippet: CART analysis using peaks obtained by SELDI-TOF-MS to discriminate between patients with MMD and control patients. The decision tree was constructed using CSF samples from 32 patients with MMD and control patients. The classification is determined starting at the roof node, following by appropriate splitting decisions based on the peak intensity at each node. If the peak intensity is lower than the cutoff intensity value, the left node is selected. This splitting process is continued until no further classification is achieved and terminal nodes are produced. Using m/z 4473, 2406 and 6338 peaks (pH 5), m/z 4588 and 7250 peaks (pH 7), and m/z 4746 and 1044 peaks (pH 9), CART for Q10 ProteinChip was applied to identify patients with MMD and control patients. The analysis correctly classified all 20 patients with MMD under pH 5 condition and 19 of 20 under the pH 7 and 9 conditions; all 12 control patients were classified under all pH conditions.

Article Snippet: The protein mass spectral data was generated with ProteinChip System 4000 SELDI-TOF mass spectrometer (Enterprise version; Bio-Rad Laboratories) using automated data collection protocol with Ciphergen Express version 3.0.6 software interface (Bio-Rad Laboratories).

Techniques: Construct, Produced

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

Article Snippet: Grus et al. ( ) , DED , Single subject, 1 take , STS , 20 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Ciphergen Express Data Manager , N/D.

Techniques: Software, Biomarker Assay

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

Article Snippet: Grus et al. ( ) , DED , Single subject, 1 take , STS , 20 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Ciphergen Express Data Manager , N/D.

Techniques: Software

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

Article Snippet: Tomosugi et al. ( ) , DED, SS , Single subject, 1 take , STS , 24 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Biomarker Wizard , 56.

Techniques: Software, Biomarker Assay

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

Article Snippet: Tomosugi et al. ( ) , DED, SS , Single subject, 1 take , STS , 24 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Biomarker Wizard , 56.

Techniques: Software

Journal: American Journal of Translational Research

Article Title: Targeting TNFα in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients

doi:

Figure Lengend Snippet: Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.

Article Snippet: ProteinChip®-captured proteins were detected using a ProteinChip® SELDI-TOF reader PCS4000 MS-TOF Enterprise (Bio-Rad).

Techniques: MANN-WHITNEY